Every Form 4 that ACURA PHARMS INC (ACUR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ACUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACUR filings page.
Acura Pharmaceuticals director Immanuel Thangaraj reported equity compensation activity involving restricted stock units (RSUs) and common stock. On January 2, 2026, 50,000 RSUs previously granted on January 2, 2025 were exchanged on a one-for-one basis into 50,000 shares of common stock, with par value of $0.01 per share paid on exchange. On the same date, he received a new grant of 50,000 RSUs under the 2021 plan, which vest 25% on the last day of each of March, June, September and December 2026, with provisions for immediate vesting upon a change of control and certain other events, and an election to take up to 40% in cash instead of shares. After these transactions, he directly holds 547,647 shares of common stock and 50,000 RSUs, and there are an additional 1,956,396 shares reported as indirectly owned by Essex Woodlands Health Ventures Fund V, L.P., where he is a managing director of the general partner and disclaims beneficial ownership except to the extent of his pecuniary interest.
Acura Pharmaceuticals director William G. Skelly reported equity compensation activity involving restricted stock units and common shares. On January 2, 2026, 50,000 restricted stock units granted on January 2, 2025 were exchanged on a one-for-one basis into 50,000 shares of common stock, with par value of $0.01 per share paid upon exchange. On the same date, Skelly received a new grant of 50,000 restricted stock units under the 2021 plan, which vest 25% on the last day of each of March, June, September and December 2026, with immediate vesting upon a change of control and certain other events. Following these transactions, Skelly beneficially owned 675,989 shares of common stock and 50,000 restricted stock units, all held directly.
Acura Pharmaceuticals director George K. Ross reported equity compensation activity involving restricted stock units (RSUs) and common stock. On January 2, 2026, he acquired 50,000 shares of common stock through an RSU exchange under the 2021 plan, bringing his directly held common stock to 595,903 shares following the transaction.
The filing also shows derivative activity in RSUs. A block of 50,000 RSUs previously granted on January 2, 2025 was exchanged on a one-for-one basis into common stock upon payment of par value of $0.01 per share. In addition, Ross was granted a new award of 50,000 RSUs on January 2, 2026, vesting 25% on the last day of each of March, June, September, and December 2026, with provisions for immediate vesting upon a change of control and certain other events and an election to take up to 40% of the RSUs in cash.